O	0	8	Proteome	Proteome	NN	B-NP
O	9	17	analysis	analysis	NN	I-NP
O	18	20	of	of	IN	B-PP
B-Cell	21	27	NIH3T3	NIH3T3	NN	B-NP
I-Cell	28	33	cells	cell	NNS	I-NP
O	34	45	transformed	transform	VBN	B-VP
O	46	48	by	by	IN	B-PP
O	49	58	activated	activate	VBN	B-NP
O	59	67	Galpha12	Galpha12	NN	I-NP
O	67	68	:	:	:	O
O	69	79	regulation	regulation	NN	B-NP
O	80	82	of	of	IN	B-PP
B-Cancer	83	91	leukemia	leukemia	NN	B-NP
O	91	92	-	-	HYPH	B-NP
O	92	102	associated	associate	VBN	I-NP
O	103	110	protein	protein	NN	I-NP
O	111	114	SET	SET	NN	I-NP
O	114	115	.	.	.	O

O	117	123	Galpha	Galpha	NN	B-NP
O	123	124	(	(	(	O
O	124	126	12	12	CD	B-NP
O	126	127	)	)	)	O
O	127	128	,	,	,	O
O	129	132	the	the	DT	B-NP
O	133	138	alpha	alpha	SYM	I-NP
O	138	139	-	-	HYPH	I-NP
O	139	146	subunit	subunit	NN	I-NP
O	147	149	of	of	IN	B-PP
O	150	153	the	the	DT	B-NP
O	154	157	G12	G12	NN	I-NP
O	158	164	family	family	NN	I-NP
O	165	167	of	of	IN	B-PP
O	168	182	heterotrimeric	heterotrimeric	JJ	B-NP
O	183	184	G	G	NN	I-NP
O	185	193	proteins	protein	NNS	I-NP
O	194	196	is	be	VBZ	B-VP
O	197	205	involved	involve	VBN	I-VP
O	206	208	in	in	IN	B-PP
O	209	212	the	the	DT	B-NP
O	213	223	regulation	regulation	NN	I-NP
O	224	226	of	of	IN	B-PP
B-Cell	227	231	cell	cell	NN	B-NP
O	232	245	proliferation	proliferation	NN	I-NP
O	246	249	and	and	CC	O
B-Cancer	250	260	neoplastic	neoplastic	JJ	B-NP
O	261	275	transformation	transformation	NN	I-NP
O	275	276	.	.	.	O

O	277	283	GTPase	GTPase	NN	B-NP
O	283	284	-	-	HYPH	B-PP
O	284	293	deficient	deficient	JJ	B-NP
O	293	294	,	,	,	I-NP
O	295	309	constitutively	constitutively	RB	I-NP
O	310	319	activated	activate	VBN	I-NP
O	320	326	mutant	mutant	NN	I-NP
O	327	329	of	of	IN	B-PP
O	330	336	Galpha	Galpha	NN	B-NP
O	336	337	(	(	(	O
O	337	339	12	12	CD	B-NP
O	339	340	)	)	)	O
O	341	342	(	(	(	O
O	342	348	Galpha	Galpha	NN	B-NP
O	348	349	(	(	(	O
O	349	351	12	12	CD	B-NP
O	351	352	)	)	)	O
O	352	357	Q229L	Q229L	NN	B-NP
O	358	360	or	or	CC	O
O	361	367	Galpha	Galpha	NN	B-NP
O	367	368	(	(	(	O
O	368	370	12	12	CD	B-NP
O	370	371	)	)	)	O
O	371	373	QL	QL	NN	B-NP
O	373	374	)	)	)	O
O	375	378	has	have	VBZ	B-VP
O	379	383	been	be	VBN	I-VP
O	384	394	previously	previously	RB	I-VP
O	395	400	shown	show	VBN	I-VP
O	401	403	to	to	TO	I-VP
O	404	410	induce	induce	VB	I-VP
O	411	420	oncogenic	oncogenic	JJ	B-NP
O	421	435	transformation	transformation	NN	I-NP
O	436	438	of	of	IN	B-PP
B-Cell	439	445	NIH3T3	NIH3T3	NN	B-NP
I-Cell	446	451	cells	cell	NNS	I-NP
O	452	461	promoting	promote	VBG	B-VP
B-Organism_substance	462	467	serum	serum	NN	B-NP
O	467	468	-	-	HYPH	B-NP
O	469	472	and	and	CC	I-NP
O	473	482	anchorage	anchorage	NN	I-NP
O	482	483	-	-	HYPH	I-NP
O	483	494	independent	independent	JJ	I-NP
O	495	501	growth	growth	NN	I-NP
O	501	502	.	.	.	O

O	503	510	Reduced	Reduce	VBN	B-NP
O	511	517	growth	growth	NN	I-NP
O	517	518	-	-	HYPH	I-NP
O	518	524	factor	factor	NN	I-NP
O	525	534	dependent	dependent	JJ	I-NP
O	534	535	,	,	,	I-NP
O	536	546	autonomous	autonomous	JJ	I-NP
B-Cell	547	551	cell	cell	NN	I-NP
O	552	558	growth	growth	NN	I-NP
O	559	564	forms	form	VBZ	B-VP
O	565	566	a	a	DT	B-NP
O	567	575	critical	critical	JJ	I-NP
O	576	584	defining	define	VBG	I-NP
O	585	590	point	point	NN	I-NP
O	591	593	at	at	IN	B-PP
O	594	599	which	which	WDT	B-NP
O	600	601	a	a	DT	B-NP
O	602	608	normal	normal	JJ	I-NP
B-Cell	609	613	cell	cell	NN	I-NP
O	614	619	turns	turn	NNS	I-NP
O	620	624	into	into	IN	B-PP
O	625	627	an	an	DT	B-NP
O	628	637	oncogenic	oncogenic	JJ	I-NP
O	638	641	one	one	NN	I-NP
O	641	642	.	.	.	O

O	643	645	To	To	TO	B-VP
O	646	654	identify	identify	VB	I-VP
O	655	658	the	the	DT	B-NP
O	659	669	underlying	underlying	JJ	I-NP
O	670	679	mechanism	mechanism	NN	I-NP
O	680	688	involved	involve	VBN	B-VP
O	689	691	in	in	IN	B-PP
O	692	696	such	such	JJ	B-NP
O	697	703	growth	growth	NN	I-NP
O	703	704	-	-	HYPH	O
O	704	710	factor	factor	NN	B-NP
O	710	711	/	/	SYM	B-NP
B-Organism_substance	711	716	serum	serum	NN	I-NP
O	717	728	independent	independent	JJ	I-NP
O	729	735	growth	growth	NN	I-NP
O	736	738	of	of	IN	B-PP
O	739	745	Galpha	Galpha	NN	B-NP
O	745	746	(	(	(	O
O	746	748	12	12	CD	B-NP
O	748	749	)	)	)	O
O	749	751	QL	QL	NN	B-NP
O	751	752	-	-	HYPH	O
O	752	763	transformed	transform	VBN	B-VP
B-Cell	764	770	NIH3T3	NIH3T3	NN	B-NP
O	770	771	,	,	,	O
O	772	774	we	we	PRP	B-NP
O	775	782	carried	carry	VBD	B-VP
O	783	786	out	out	RP	B-PRT
O	787	788	a	a	DT	B-NP
O	789	792	two	two	CD	I-NP
O	792	793	-	-	HYPH	I-NP
O	793	804	dimensional	dimensional	JJ	I-NP
O	805	817	differential	differential	JJ	I-NP
O	818	826	proteome	proteome	NN	I-NP
O	827	835	analysis	analysis	NN	I-NP
O	836	838	of	of	IN	B-PP
O	839	845	Galpha	Galpha	NN	B-NP
O	845	846	(	(	(	O
O	846	848	12	12	CD	B-NP
O	848	849	)	)	)	O
O	849	851	QL	QL	NN	B-NP
O	851	852	-	-	HYPH	B-NP
O	852	863	transformed	transform	VBN	I-NP
B-Cell	864	870	NIH3T3	NIH3T3	NN	I-NP
I-Cell	871	876	cells	cell	NNS	I-NP
O	877	880	and	and	CC	O
B-Cell	881	886	cells	cell	NNS	B-NP
O	887	897	expressing	express	VBG	B-VP
O	898	904	vector	vector	NN	B-NP
O	905	912	control	control	NN	I-NP
O	912	913	.	.	.	O

O	914	918	This	This	DT	B-NP
O	919	927	analysis	analysis	NN	I-NP
O	928	936	revealed	reveal	VBD	B-VP
O	937	938	a	a	DT	B-NP
O	939	944	total	total	NN	I-NP
O	945	947	of	of	IN	B-PP
O	948	950	22	22	CD	B-NP
O	951	958	protein	protein	NN	I-NP
O	958	959	-	-	HYPH	O
O	959	964	spots	spot	NNS	B-NP
O	965	970	whose	whose	WP$	B-NP
O	971	981	expression	expression	NN	I-NP
O	982	985	was	be	VBD	B-VP
O	986	993	altered	alter	VBN	I-VP
O	994	996	by	by	IN	B-PP
O	997	1001	more	more	JJR	B-NP
O	1002	1006	than	than	IN	I-NP
O	1007	1008	3	3	CD	I-NP
O	1008	1009	-	-	HYPH	I-NP
O	1009	1014	folds	fold	NNS	I-NP
O	1014	1015	.	.	.	O

O	1016	1019	Two	Two	CD	B-NP
O	1020	1022	of	of	IN	B-PP
O	1023	1028	these	these	DT	B-NP
O	1029	1034	spots	spot	NNS	I-NP
O	1035	1039	were	be	VBD	B-VP
O	1040	1050	identified	identify	VBN	I-VP
O	1051	1053	by	by	IN	B-PP
O	1054	1059	MALDI	MALDI	NN	B-NP
O	1059	1060	-	-	HYPH	I-NP
O	1060	1062	MS	MS	NN	I-NP
O	1063	1071	analysis	analysis	NN	I-NP
O	1072	1074	as	as	IN	B-PP
O	1075	1088	proliferating	proliferate	VBG	B-VP
O	1089	1093	cell	cell	NN	B-NP
O	1094	1101	nuclear	nuclear	JJ	I-NP
O	1102	1109	antigen	antigen	NN	I-NP
O	1110	1111	(	(	(	O
O	1111	1115	PCNA	PCNA	NN	B-NP
O	1115	1116	)	)	)	O
O	1117	1120	and	and	CC	O
B-Cancer	1121	1128	myeloid	myeloid	JJ	B-NP
I-Cancer	1128	1129	-	-	HYPH	I-NP
I-Cancer	1129	1137	leukemia	leukemia	NN	I-NP
O	1137	1138	-	-	HYPH	B-NP
O	1138	1148	associated	associate	VBN	I-NP
O	1149	1152	SET	SET	NN	I-NP
O	1153	1160	protein	protein	NN	I-NP
O	1160	1161	.	.	.	O

O	1162	1165	The	The	DT	B-NP
O	1166	1175	increased	increase	VBN	I-NP
O	1176	1187	expressions	expression	NNS	I-NP
O	1188	1190	of	of	IN	B-PP
O	1191	1196	these	these	DT	B-NP
O	1197	1205	proteins	protein	NNS	I-NP
O	1206	1208	in	in	IN	B-PP
B-Cell	1209	1215	Galpha	Galpha	NN	B-NP
I-Cell	1215	1216	(	(	(	O
I-Cell	1216	1218	12	12	CD	B-NP
I-Cell	1218	1219	)	)	)	O
I-Cell	1219	1221	QL	QL	NN	B-NP
I-Cell	1222	1227	cells	cell	NNS	I-NP
O	1228	1232	were	be	VBD	B-VP
O	1233	1242	validated	validate	VBN	I-VP
O	1243	1245	by	by	IN	B-PP
O	1246	1256	immunoblot	immunoblot	NN	B-NP
O	1257	1265	analysis	analysis	NN	I-NP
O	1265	1266	.	.	.	O

O	1267	1278	Furthermore	Furthermore	RB	B-ADVP
O	1278	1279	,	,	,	O
O	1280	1289	transient	transient	JJ	B-NP
O	1290	1302	transfection	transfection	NN	I-NP
O	1303	1310	studies	study	NNS	I-NP
O	1311	1315	with	with	IN	B-PP
B-Cell	1316	1322	NIH3T3	NIH3T3	NN	B-NP
I-Cell	1323	1328	cells	cell	NNS	I-NP
O	1329	1338	indicated	indicate	VBD	B-VP
O	1339	1343	that	that	IN	B-SBAR
O	1344	1347	the	the	DT	B-NP
O	1348	1358	expression	expression	NN	I-NP
O	1359	1361	of	of	IN	B-PP
O	1362	1371	activated	activate	VBN	B-NP
O	1372	1378	Galpha	Galpha	NN	I-NP
O	1378	1379	(	(	(	O
O	1379	1381	12	12	CD	B-NP
O	1381	1382	)	)	)	O
O	1383	1390	readily	readily	RB	B-ADVP
O	1391	1400	increased	increase	VBD	B-VP
O	1401	1404	the	the	DT	B-NP
O	1405	1415	expression	expression	NN	I-NP
O	1416	1418	of	of	IN	B-PP
O	1419	1422	SET	SET	NN	B-NP
O	1423	1430	protein	protein	NN	I-NP
O	1431	1433	by	by	IN	B-PP
O	1434	1436	24	24	CD	B-NP
O	1437	1438	h	h	NN	I-NP
O	1438	1439	.	.	.	O

O	1440	1442	As	As	IN	B-SBAR
O	1443	1446	SET	SET	NN	B-NP
O	1447	1450	has	have	VBZ	B-VP
O	1451	1455	been	be	VBN	I-VP
O	1456	1466	previously	previously	RB	I-VP
O	1467	1475	reported	report	VBN	I-VP
O	1476	1478	to	to	TO	I-VP
O	1479	1481	be	be	VB	I-VP
O	1482	1484	an	an	DT	B-NP
O	1485	1494	inhibitor	inhibitor	NN	I-NP
O	1495	1497	of	of	IN	B-PP
O	1498	1509	phosphatase	phosphatase	NN	B-NP
O	1510	1514	PP2A	PP2A	NN	I-NP
O	1514	1515	,	,	,	O
O	1516	1519	the	the	DT	B-NP
B-Cellular_component	1520	1527	nuclear	nuclear	JJ	I-NP
O	1528	1539	phosphatase	phosphatase	NN	I-NP
O	1540	1548	activity	activity	NN	I-NP
O	1549	1552	was	be	VBD	B-VP
O	1553	1562	monitored	monitor	VBN	I-VP
O	1563	1565	in	in	IN	B-PP
B-Cell	1566	1571	cells	cell	NNS	B-NP
O	1572	1582	expressing	express	VBG	B-VP
O	1583	1592	activated	activate	VBN	B-NP
O	1593	1599	Galpha	Galpha	NN	I-NP
O	1599	1600	(	(	(	O
O	1600	1602	12	12	CD	B-NP
O	1602	1603	)	)	)	O
O	1603	1604	.	.	.	O

O	1605	1608	Our	Our	PRP$	B-NP
O	1609	1616	results	result	NNS	I-NP
O	1617	1625	indicate	indicate	VBP	B-VP
O	1626	1630	that	that	IN	B-SBAR
O	1631	1634	the	the	DT	B-NP
B-Cellular_component	1635	1642	nuclear	nuclear	JJ	I-NP
O	1643	1654	phosphatase	phosphatase	NN	I-NP
O	1655	1663	activity	activity	NN	I-NP
O	1664	1666	is	be	VBZ	B-VP
O	1667	1676	inhibited	inhibit	VBN	I-VP
O	1677	1679	by	by	IN	B-PP
O	1680	1687	greater	great	JJR	B-NP
O	1688	1692	than	than	IN	I-NP
O	1693	1695	50	50	CD	I-NP
O	1695	1696	%	%	NN	I-NP
O	1697	1699	in	in	IN	B-PP
B-Cell	1700	1706	Galpha	Galpha	NN	B-NP
I-Cell	1706	1707	(	(	(	O
I-Cell	1707	1709	12	12	CD	B-NP
I-Cell	1709	1710	)	)	)	O
I-Cell	1710	1712	QL	QL	NN	B-NP
I-Cell	1713	1718	cells	cell	NNS	I-NP
O	1719	1727	compared	compare	VBN	B-VP
O	1728	1730	to	to	TO	B-PP
O	1731	1737	vector	vector	NN	B-NP
O	1738	1745	control	control	NN	I-NP
B-Cell	1746	1751	cells	cell	NNS	I-NP
O	1751	1752	.	.	.	O

O	1753	1757	Thus	Thus	RB	B-ADVP
O	1757	1758	,	,	,	O
O	1759	1762	our	our	PRP$	B-NP
O	1763	1770	results	result	NNS	I-NP
O	1771	1775	from	from	IN	B-PP
O	1776	1788	differential	differential	JJ	B-NP
O	1789	1797	proteome	proteome	NN	I-NP
O	1798	1806	analysis	analysis	NN	I-NP
O	1807	1816	presented	present	VBN	B-VP
O	1817	1821	here	here	RB	B-ADVP
O	1822	1828	report	report	NN	B-NP
O	1829	1832	for	for	IN	B-PP
O	1833	1836	the	the	DT	B-NP
O	1837	1842	first	first	JJ	I-NP
O	1843	1847	time	time	NN	I-NP
O	1848	1849	a	a	DT	B-NP
O	1850	1854	role	role	NN	I-NP
O	1855	1858	for	for	IN	B-PP
O	1859	1862	SET	SET	NN	B-NP
O	1863	1865	in	in	IN	B-PP
O	1866	1872	Galpha	Galpha	NN	B-NP
O	1872	1873	(	(	(	O
O	1873	1875	12	12	CD	B-NP
O	1875	1876	)	)	)	O
O	1876	1877	-	-	HYPH	O
O	1877	1885	mediated	mediate	VBN	B-NP
O	1886	1895	signaling	signaling	NN	I-NP
O	1896	1904	pathways	pathway	NNS	I-NP
O	1905	1908	and	and	CC	O
O	1909	1910	a	a	DT	B-NP
O	1911	1915	role	role	NN	I-NP
O	1916	1919	for	for	IN	B-PP
O	1920	1926	Galpha	Galpha	NN	B-NP
O	1926	1927	(	(	(	O
O	1927	1929	12	12	CD	B-NP
O	1929	1930	)	)	)	O
O	1931	1933	in	in	IN	B-PP
O	1934	1937	the	the	DT	B-NP
O	1938	1948	regulation	regulation	NN	I-NP
O	1949	1951	of	of	IN	B-PP
O	1952	1955	the	the	DT	B-NP
B-Cancer	1956	1964	leukemia	leukemia	NN	I-NP
O	1964	1965	-	-	HYPH	B-VP
O	1965	1975	associated	associate	VBN	B-NP
O	1976	1979	SET	SET	NN	I-NP
O	1979	1980	-	-	HYPH	O
O	1980	1987	protein	protein	NN	B-NP
O	1988	1998	expression	expression	NN	I-NP
O	1998	1999	.	.	.	O

